Pharmacotherapy for uveitis: current management and emerging therapy

Robert J Barry, Quan Dong Nguyen, Richard W Lee, Philip I Murray, Alastair K Denniston

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)


Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.

Original languageEnglish
Pages (from-to)1891-911
Number of pages21
JournalClinical Ophthalmology
Publication statusPublished - 22 Sept 2014


Dive into the research topics of 'Pharmacotherapy for uveitis: current management and emerging therapy'. Together they form a unique fingerprint.

Cite this